NCT02607683View on ClinicalTrials.gov

Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 1, 2016

Primary Completion Date

September 19, 2016

Study Completion Date

October 31, 2016

Conditions
Steatoblepharon
Interventions
DRUG

XAF5 (concentration A: 0.1%)

DRUG

XAF5 (concentration B: 0.035%)

DRUG

Matching placebo

Trial Locations (6)

Unknown

David Wirta, MD, Inc., Newport Beach

OC Clinical Trials, Santa Ana

Danbury Eye Physicians, Danbury

Opthalmic Consultants of Boston, Boston

South Shore Eye Care, Inc., Wantagh

Cincinatti Eye Institute, Cincinnati

All Listed Sponsors
lead

Topokine Therapeutics, Inc.

INDUSTRY

NCT02607683 - Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags) | Biotech Hunter | Biotech Hunter